Warning: fopen(/home/virtual/enm-kes/journal/upload/ip_log/ip_log_2024-12.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 100 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 101
Division of Endocrinology and Metabolism, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea
Copyright © 2023 Korean Endocrine Society
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was reported.
AUTHOR CONTRIBUTIONS
Conception or design: J.Y.P., W.C., A.R.H., J.H.Y., H.K.K., H.C.K. Acquisition, analysis, or interpretation of data: J.Y.P., W.C., A.R.H., J.H.Y., H.K.K., H.C.K. Drafting the work or revising: J.Y.P., H.K.K. Final approval of the manuscript: J.Y.P., H.K.K.
Study | Country recruitment period | Study design | No. of cases/patients | Age, yr | Female, % | Needle gauge | Outcomes | |
---|---|---|---|---|---|---|---|---|
Pain after FNA | ||||||||
Lee et al. (2019) [12] | South Korea 2018 | Randomized, double-blind | 99/99 (23G n=49, 25G n=50) | 51.5 | 79.8 | 23, 25 | Rated with NRSa | |
23G: none 3 (6.1%), mild 39 (79.6%), moderate 6 (12.2%), severe 1 (2.0%) | ||||||||
25G: none 10 (20%), mild 36 (72.0%), moderate 4 (8.0%), severe 0 (0.0%) | ||||||||
Jung et al. (2018) [13] | South Korea 2017 | Retrospective | 88/88 (21G n=38, 23G n=50) | 54.6 | 84.1 | 21, 23 | Rated with NRSa | |
21G: none 1 (2.6%), mild 33 (86.8%), moderate 4 (10.5%), severe 0 (0.0%) | ||||||||
23G: none 6 (12.0%), mild 42 (84.0%), moderate 2 (4.0%) severe 0 (0.0%) | ||||||||
Cordes et al. (2018) [14] | Germany 2017–2018 | Prospective | 205/205 | 55 | 71.2 | 22, 24 | Pain at the puncture site 5 (2.4%) | |
Birgi et al. (2016) [11] | Turkey 2014 | Prospective | 138/138 | 49.4 | 88.4 | 21 | No pain 33.3% | |
Pain 66.6% (low 48.3% medium 15.7%, high 2.7%) | ||||||||
Toman et al. (2016) [15] | Turkey 2012 | Retrospective | 98/98 | 49.8 | 82.7 | 23 | 100-mm VAS ≥30 (70.5%) | |
A higher pain score correlated with the nodule depth (r=0.43, P<0.001) | ||||||||
Lee et al. (2013) [16] | South Korea 2012 | Retrospective | 157/157 (experienced radiologist n=75, less experienced radiologist n=82) | 51.4 | 89.2 | 23 | Rated with NRSa | |
Experienced radiologist: none 14 (18.7%), mild 48 (64.0%), moderate 11 (14.7%), severe 3 (4.0%) | ||||||||
Less experienced radiologist: none 12 (14.6%), mild 48 (58.5%), moderate 20 (24.4%), severe 5 (6.1%) | ||||||||
Kim et al. (2012) [10] | South Korea 2007–2009 | Retrospective | 1,456/977 | 49.0 | 85.8 | 23 | Mild pain 87 (8.9%) | |
No other major complications | ||||||||
Gursoy et al. (2007) [18] | Turkey Apr.–Sep. 2006 | Randomized, double-blind | 99/99 (placebo n=49, EMLA n=50) | 46.8 | 19.5 | 25 | Rated with VRS | |
Placebo group: none 4, mild 16 (32.7%), moderate 14 (28.6%), severe 15 (30.6%) | ||||||||
EMLA group: none 9 (18%), mild 26 (52%), moderate 11 (22%), severe 4 (8%) | ||||||||
Gursoy et al. (2007) [17] | Turkey Aug.–Dec. 2006 | Randomized, double-blind | 107/107 (placebo n=52, lidocaine n=55) | 46.5 | 15.6 | 25 | Rated with VRS | |
Placebo group: none 6 (11.5%), mild 17 (32.7%), moderate 14 (26.9%), severe 15 (28.8%) | ||||||||
Lidocaine group: none 23 (41.8%), mild 27 (49.1%), moderate 5 (9.1%), severe 0 (0%) | ||||||||
Hematoma or any bleeding events after the procedure | ||||||||
Ahn et al. (2021) [22] | South Korea 2010–2014 | Retrospective | 627/583 | 49.6 | 67.5 | 23 | Comparison with the CNB group | |
FNAB group 0 (0.0%) | ||||||||
Kim et al. (2019) [23] | South Korea 2015 | Retrospective | 87/87 | 52.5 | 87.4 | 26 | Subcapsular hematoma 3 (3.4%) | |
Khadra et al. (2018) [28] | USA 2008–2016 | Retrospective | 1,568/802 | 63.0 (AT/AC) | 80.2 | 25 | Total 9/1,568 (0.6%) | |
50.1 (control) | AT/AC 3/336 (0.9%) | |||||||
No agent 6/1,232 (0.5%) | ||||||||
Jung et al. (2018) [13] | South Korea 2017 | Retrospective | 88/88 | 54.6 | 84.1 | 21, 23 | Intrathyroidal 1 (2.6%) | |
Cordes et al. (2018) [14] | Germany 2017–2018 | Prospective | 205/205 | 55 | 71.2 | 22, 24 | Minor hematomas 2 (0.9%) | |
Kavanagh et al. (2017) [19] | Ireland 2006–2013 | Retrospective | 724/724 | 40 | 82.5 | 20, 23 | Post-procedural 6 (0.8%) | |
Chae et al. (2017) [24] | South Korea 2013–2015 | Retrospective | 5,121/5,121 | 50.9 | 78.8 | 23 | Comparison with the CNB group FNAB group 43 (0.8%) | |
Cappelli et al. (2017) [21] | Italy 2007–2016 | Retrospective | 7,449/6,323 | 54.3 | 81.0 | 25 | Intrathyroidal 4 (0.06%) | |
Carotid intramural 1 (0.02%) | ||||||||
Birgi et al. (2016) [11] | Turkey 2014 | Prospective | 138/138 | 49.4 | 88.4 | 21 | Minor hematoma 1 (0.7%) | |
Uchida et al. (2016) [27] | Japan 2011–2013 | Retrospective | 742/653 | 59.0 | 74.1 | 22 | Acute thyroid swelling or anechoic lesions 8 (1.2%) | |
Chen et al. (2015) [26] | USA 2007–2011 | Retrospective | 96/96 | 56.0 | 83.0 | 25, 27 | Local hematoma 1 (1.0%) | |
Lee et al. (2013) [16] | South Korea 2012 | Retrospective | 157/157 | 51.4 | 89.2 | 23 | Small intraglandular hematoma 1 (0.6%) | |
Abu-Yousef et al. (2011) [29] | USA 2006–2007 | Retrospective | 788/593 | NR | NR | 22, 25 | Including AT/AC patients | |
AT/AC 2 (1.4%) | ||||||||
Control 4 (0.9%) | ||||||||
Khoo et al. (2008) [25] | USA 1999–2001 | Retrospective | 311/311 | 54.6 | 74.3 | NR | Compared with FNAB+CNB group | |
FNAB-only group 3 (1%) | ||||||||
Newkirk et al. (2000) [20] | USA 1996–1998 | Retrospective | 234/215 | 51.9 (female) | 82.9 | 22, 23, 25 | Perithyroidal or superficial 15 (6.4%) | |
57.8 (male) | ||||||||
Neurological symptoms | ||||||||
Cordes et al. (2018) [14] | Germany 2017–2018 | Prospective | 205/205 | 55 | 71.2 | 22, 24 | Total complications 9 (4.4%) | |
Paresthesia 8 (3.9%) | ||||||||
Dysphonia 1 (0.5%) | ||||||||
Kavanagh et al. (2017) [19] | Ireland 2006–2013 | Retrospective | 724/724 | 40 | 82.5 | 20, 23 | Vasovagal reaction 2 (0.3%) | |
Cappelli et al. (2017) [21] | Italy 2007–2016 | Retrospective | 7,449/6,323 | 54.3 | 81.0 | 25 | Vasovagal reaction 1 (0.02%) | |
Tomoda et al. (2006) [30] | Japan 2004–2005 | Retrospective | 10,974/10,974 | NR | NR | 23 | Transient vocal cord paralysis 4 (0.04%) | |
Newkirk et al. (2000) [20] | USA 1996–1998 | Retrospective | 234/215 | 51.9 (female) | 82.9 | 22, 23, 25 | Hoarseness (transient) 2 (0.9%) | |
57.8 (male) | Vasovagal reaction 3 (1.3%) | |||||||
Tracheal puncture during the procedure | ||||||||
Cappelli et al. (2017) [21] | Italy 2007–2016 | Retrospective | 7,449/6,323 | 54.3 | 81.0 | 25 | Tracheal puncture 2 (0.04%) | |
Needle tract implantation of thyroid cancer | ||||||||
Hayashi et al. (2020) [33] | Japan 2006–2017 | Retrospective | 11,745/11,745 | 70.6 | NR | NR | NTI in thyroid 22 (0.19%) | |
Cappelli et al. (2017) [21] | Italy 2007–2016 | Retrospective | 7,449/6,323 | 54.3 | 81.0 | 25 | Cancer seeding along the track of the needle 1 (0.02%) | |
Ito et al. (2005) [31] | Japan 1990–2002 | Retrospective | 4,912/4,912 | NR | NR | 22 | Needle tract implantation of papillary thyroid carcinoma 7 (0.14%) |
FNA, fine-needle aspiration; NRS, numeric rating scale; VAS, visual analogue scale; EMLA, eutectic mixture of local anesthetics; VRS, verbal rating scale; CNB, core needle biopsy; FNAB, fine-needle aspiration biopsy; AT/AC, antithrombotic/anticoagulant agent; NR, not reported; NTI, needle tract implantation.
a Patients who were scored with an NRS (numeric rating scale) were regrouped as mild (1–3), moderate (4–6), and severe (7–10).
Study | Country recruitment period | Study design | No. of cases/patients | Age, yr | Female, % | Needle gauge | Outcomes | |
---|---|---|---|---|---|---|---|---|
Pain after FNA | ||||||||
Lee et al. (2019) [12] | South Korea 2018 | Randomized, double-blind | 99/99 (23G n=49, 25G n=50) | 51.5 | 79.8 | 23, 25 | Rated with NRS |
|
23G: none 3 (6.1%), mild 39 (79.6%), moderate 6 (12.2%), severe 1 (2.0%) | ||||||||
25G: none 10 (20%), mild 36 (72.0%), moderate 4 (8.0%), severe 0 (0.0%) | ||||||||
Jung et al. (2018) [13] | South Korea 2017 | Retrospective | 88/88 (21G n=38, 23G n=50) | 54.6 | 84.1 | 21, 23 | Rated with NRS |
|
21G: none 1 (2.6%), mild 33 (86.8%), moderate 4 (10.5%), severe 0 (0.0%) | ||||||||
23G: none 6 (12.0%), mild 42 (84.0%), moderate 2 (4.0%) severe 0 (0.0%) | ||||||||
Cordes et al. (2018) [14] | Germany 2017–2018 | Prospective | 205/205 | 55 | 71.2 | 22, 24 | Pain at the puncture site 5 (2.4%) | |
Birgi et al. (2016) [11] | Turkey 2014 | Prospective | 138/138 | 49.4 | 88.4 | 21 | No pain 33.3% | |
Pain 66.6% (low 48.3% medium 15.7%, high 2.7%) | ||||||||
Toman et al. (2016) [15] | Turkey 2012 | Retrospective | 98/98 | 49.8 | 82.7 | 23 | 100-mm VAS ≥30 (70.5%) | |
A higher pain score correlated with the nodule depth (r=0.43, P<0.001) | ||||||||
Lee et al. (2013) [16] | South Korea 2012 | Retrospective | 157/157 (experienced radiologist n=75, less experienced radiologist n=82) | 51.4 | 89.2 | 23 | Rated with NRS |
|
Experienced radiologist: none 14 (18.7%), mild 48 (64.0%), moderate 11 (14.7%), severe 3 (4.0%) | ||||||||
Less experienced radiologist: none 12 (14.6%), mild 48 (58.5%), moderate 20 (24.4%), severe 5 (6.1%) | ||||||||
Kim et al. (2012) [10] | South Korea 2007–2009 | Retrospective | 1,456/977 | 49.0 | 85.8 | 23 | Mild pain 87 (8.9%) | |
No other major complications | ||||||||
Gursoy et al. (2007) [18] | Turkey Apr.–Sep. 2006 | Randomized, double-blind | 99/99 (placebo n=49, EMLA n=50) | 46.8 | 19.5 | 25 | Rated with VRS | |
Placebo group: none 4, mild 16 (32.7%), moderate 14 (28.6%), severe 15 (30.6%) | ||||||||
EMLA group: none 9 (18%), mild 26 (52%), moderate 11 (22%), severe 4 (8%) | ||||||||
Gursoy et al. (2007) [17] | Turkey Aug.–Dec. 2006 | Randomized, double-blind | 107/107 (placebo n=52, lidocaine n=55) | 46.5 | 15.6 | 25 | Rated with VRS | |
Placebo group: none 6 (11.5%), mild 17 (32.7%), moderate 14 (26.9%), severe 15 (28.8%) | ||||||||
Lidocaine group: none 23 (41.8%), mild 27 (49.1%), moderate 5 (9.1%), severe 0 (0%) | ||||||||
Hematoma or any bleeding events after the procedure | ||||||||
Ahn et al. (2021) [22] | South Korea 2010–2014 | Retrospective | 627/583 | 49.6 | 67.5 | 23 | Comparison with the CNB group | |
FNAB group 0 (0.0%) | ||||||||
Kim et al. (2019) [23] | South Korea 2015 | Retrospective | 87/87 | 52.5 | 87.4 | 26 | Subcapsular hematoma 3 (3.4%) | |
Khadra et al. (2018) [28] | USA 2008–2016 | Retrospective | 1,568/802 | 63.0 (AT/AC) | 80.2 | 25 | Total 9/1,568 (0.6%) | |
50.1 (control) | AT/AC 3/336 (0.9%) | |||||||
No agent 6/1,232 (0.5%) | ||||||||
Jung et al. (2018) [13] | South Korea 2017 | Retrospective | 88/88 | 54.6 | 84.1 | 21, 23 | Intrathyroidal 1 (2.6%) | |
Cordes et al. (2018) [14] | Germany 2017–2018 | Prospective | 205/205 | 55 | 71.2 | 22, 24 | Minor hematomas 2 (0.9%) | |
Kavanagh et al. (2017) [19] | Ireland 2006–2013 | Retrospective | 724/724 | 40 | 82.5 | 20, 23 | Post-procedural 6 (0.8%) | |
Chae et al. (2017) [24] | South Korea 2013–2015 | Retrospective | 5,121/5,121 | 50.9 | 78.8 | 23 | Comparison with the CNB group FNAB group 43 (0.8%) | |
Cappelli et al. (2017) [21] | Italy 2007–2016 | Retrospective | 7,449/6,323 | 54.3 | 81.0 | 25 | Intrathyroidal 4 (0.06%) | |
Carotid intramural 1 (0.02%) | ||||||||
Birgi et al. (2016) [11] | Turkey 2014 | Prospective | 138/138 | 49.4 | 88.4 | 21 | Minor hematoma 1 (0.7%) | |
Uchida et al. (2016) [27] | Japan 2011–2013 | Retrospective | 742/653 | 59.0 | 74.1 | 22 | Acute thyroid swelling or anechoic lesions 8 (1.2%) | |
Chen et al. (2015) [26] | USA 2007–2011 | Retrospective | 96/96 | 56.0 | 83.0 | 25, 27 | Local hematoma 1 (1.0%) | |
Lee et al. (2013) [16] | South Korea 2012 | Retrospective | 157/157 | 51.4 | 89.2 | 23 | Small intraglandular hematoma 1 (0.6%) | |
Abu-Yousef et al. (2011) [29] | USA 2006–2007 | Retrospective | 788/593 | NR | NR | 22, 25 | Including AT/AC patients | |
AT/AC 2 (1.4%) | ||||||||
Control 4 (0.9%) | ||||||||
Khoo et al. (2008) [25] | USA 1999–2001 | Retrospective | 311/311 | 54.6 | 74.3 | NR | Compared with FNAB+CNB group | |
FNAB-only group 3 (1%) | ||||||||
Newkirk et al. (2000) [20] | USA 1996–1998 | Retrospective | 234/215 | 51.9 (female) | 82.9 | 22, 23, 25 | Perithyroidal or superficial 15 (6.4%) | |
57.8 (male) | ||||||||
Neurological symptoms | ||||||||
Cordes et al. (2018) [14] | Germany 2017–2018 | Prospective | 205/205 | 55 | 71.2 | 22, 24 | Total complications 9 (4.4%) | |
Paresthesia 8 (3.9%) | ||||||||
Dysphonia 1 (0.5%) | ||||||||
Kavanagh et al. (2017) [19] | Ireland 2006–2013 | Retrospective | 724/724 | 40 | 82.5 | 20, 23 | Vasovagal reaction 2 (0.3%) | |
Cappelli et al. (2017) [21] | Italy 2007–2016 | Retrospective | 7,449/6,323 | 54.3 | 81.0 | 25 | Vasovagal reaction 1 (0.02%) | |
Tomoda et al. (2006) [30] | Japan 2004–2005 | Retrospective | 10,974/10,974 | NR | NR | 23 | Transient vocal cord paralysis 4 (0.04%) | |
Newkirk et al. (2000) [20] | USA 1996–1998 | Retrospective | 234/215 | 51.9 (female) | 82.9 | 22, 23, 25 | Hoarseness (transient) 2 (0.9%) | |
57.8 (male) | Vasovagal reaction 3 (1.3%) | |||||||
Tracheal puncture during the procedure | ||||||||
Cappelli et al. (2017) [21] | Italy 2007–2016 | Retrospective | 7,449/6,323 | 54.3 | 81.0 | 25 | Tracheal puncture 2 (0.04%) | |
Needle tract implantation of thyroid cancer | ||||||||
Hayashi et al. (2020) [33] | Japan 2006–2017 | Retrospective | 11,745/11,745 | 70.6 | NR | NR | NTI in thyroid 22 (0.19%) | |
Cappelli et al. (2017) [21] | Italy 2007–2016 | Retrospective | 7,449/6,323 | 54.3 | 81.0 | 25 | Cancer seeding along the track of the needle 1 (0.02%) | |
Ito et al. (2005) [31] | Japan 1990–2002 | Retrospective | 4,912/4,912 | NR | NR | 22 | Needle tract implantation of papillary thyroid carcinoma 7 (0.14%) |
Pain | Smaller needle gauge |
Local anesthesia (for patients sensitive to pain, anxious about the procedure, or with thyroid nodules in the deep portion) | |
Hematoma | Investigate the bleeding tendency, discontinue AC/AT depending on individual circumstances |
Doppler ultrasonography (to find thyroid nodules with high vascularity) | |
Careful procedure for elderly patients (due to increased venous fragility and possible arteriovenous shunts) | |
NTI | Cautious procedure when withdrawing the needle following FNAB |
Thorough follow-up ultrasonography to detect NTI | |
Vocal cord injury | Avoid puncturing the dorsal part of the nodule |
Evaluate the vascularity of the thyroid nodule before FNAB | |
Infection | Sterile procedure, especially for immunocompromised patients (diabetes, cancer, atopic dermatitis, etc.) |
Early suspicion with empirical antibiotic treatment and drainage to prevent life-threatening conditions | |
Post-aspiration thyrotoxicosis | Early suspicion if patients have symptoms of thyrotoxicosis, and perform thyroid function tests |
FNA, fine-needle aspiration; NRS, numeric rating scale; VAS, visual analogue scale; EMLA, eutectic mixture of local anesthetics; VRS, verbal rating scale; CNB, core needle biopsy; FNAB, fine-needle aspiration biopsy; AT/AC, antithrombotic/anticoagulant agent; NR, not reported; NTI, needle tract implantation. Patients who were scored with an NRS (numeric rating scale) were regrouped as mild (1–3), moderate (4–6), and severe (7–10).
FNAB, fine-needle aspiration biopsy; AC/AT, anticoagulants and antithrombotic agent; NTI, needle tract implantation.